The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders

Pharmacol Biochem Behav. 2022 Feb:213:173321. doi: 10.1016/j.pbb.2021.173321. Epub 2022 Jan 15.

Abstract

GABAkines, or positive allosteric modulators of γ-aminobutyric acid-A (GABAA) receptors, are used for the treatment of anxiety, epilepsy, sleep, and other disorders. The search for improved GABAkines, with reduced safety liabilities (e.g., dependence) or side-effect profiles (e.g., sedation) constituted multiple discovery and development campaigns that involved a multitude of strategies over the past century. Due to the general lack of success in the development of new GABAkines, there had been a decades-long draught in bringing new GABAkines to market. Recently, however, there has been a resurgence of efforts to bring GABAkines to patients, the FDA approval of the neuroactive steroid brexanolone for post-partum depression in 2019 being the first. Other neuroactive steroids are in various stages of clinical development (ganaxolone, zuranolone, LYT-300, Sage-324, PRAX 114, and ETX-155). These GABAkines and non-steroid compounds (GRX-917, a TSPO binding site ligand), darigabat (CVL-865), an α2/3/5-preferring GABAkine, SAN711, an α3-preferring GABAkine, and the α2/3-preferring GABAkine, KRM-II-81, bring new therapeutic promise to this highly utilized medicinal target in neurology and psychiatry. Herein, we also discuss possible conditions that have enabled the transition to a new age of GABAkines. We highlight the pharmacology of KRM-II-81 that has the most preclinical data reported. KRM-II-81 is the lead compound in a new series of orally bioavailable imidazodiazepines entering IND-enabling safety studies. KRM-II-81 has a preclinical profile predicting efficacy against pharmacoresistant epilepsies, traumatic brain injury, and neuropathic pain. KRM-II-81 also produces anxiolytic- and antidepressant-like effects in rodent models. Other key features of the pharmacology of this compound are its low sedation rate, lack of tolerance development, and the ability to prevent the development of seizure sensitization.

Keywords: Anxiety; Depression; Epilepsy; GABAkines; KRM-II-81; Neuroactive steroids; Pain.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Animals
  • Anti-Anxiety Agents / therapeutic use
  • Anticonvulsants / therapeutic use
  • Antidepressive Agents / therapeutic use
  • Anxiety / drug therapy
  • Epilepsy / drug therapy
  • GABA Agents / pharmacology
  • GABA Agents / therapeutic use*
  • GABA-A Receptor Agonists / therapeutic use
  • Humans
  • Mental Disorders / drug therapy*
  • Nervous System Diseases / drug therapy*
  • Neuralgia / drug therapy
  • Oxazoles / pharmacology
  • Oxazoles / therapeutic use*
  • Receptors, GABA / metabolism*
  • Receptors, GABA-A / metabolism
  • Seizures / drug therapy

Substances

  • Anti-Anxiety Agents
  • Anticonvulsants
  • Antidepressive Agents
  • GABA Agents
  • GABA-A Receptor Agonists
  • KRM-II-81
  • Oxazoles
  • Receptors, GABA
  • Receptors, GABA-A